APAC The global AI-in-clinical-trials market is forecast to grow at a 22.6 percent CAGR through 2030, reaching roughly USD 6.5 billion, as sponsors push CROs to demonstrate concrete efficiency gains rather than incremental process tweaks. That growth is already visible on the ground in APAC: AI has moved well beyond the…
Korea Korea’s position as a clinical trials hub did not happen overnight. The country has treated clinical development as a matter of deliberate government policy for the better part of two decades, with Korea ranking among the world’s leading trial destinations as far back as 2018; years before China’s biotech ambitions…
Europe The goal is not only to generate scientific breakthroughs, but to ensure that these breakthroughs reach patients faster and more reliably Professor Gerd Geisslinger serves as Chair of Clinical Pharmacology at Goethe University Hospital and as Executive Director of the Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), which is…
Korea But Korea is genuinely active, with strong resources – scientifically sound, capable, and very motivated Kyong Hwa Park, Professor of Medical Oncology at Korea University College of Medicine, reflects on Korea’s transformation into a global oncology research hub, highlighting the impact of the K-MASTER precision medicine initiative, advances in cancer…
Korea Jinhak Kim, Executive Director and President US at C&R Research, describes the company’s evolution into a global, data-driven CRO. He outlines its strategy of matching clinical trials to regions based on cost and patient access, expanding into Southeast Asia and the US, integrating AI, and supporting biotechs with end-to-end services…
USA For many years, the US has been considered the unequivocal champion in the global war against cancer. Not only does the country presently account for approximately 57 percent of worldwide cancer research funding, but American per capita investment in oncology research averages as much as seven times higher than that…
USA Nasha Fitter, a tech entrepreneur and CEO of the FOXG1 Research Foundation, discusses the radical shift in drug development led by a new generation of sophisticated parent-entrepreneurs. Following her daughter’s diagnosis with the ultra-rare neurodevelopmental disorder FOXG1 syndrome, Fitter co-founded the FOXG1 Research Foundation and Citizen Health. Her mission: to…
USA How can rare disease innovation move faster without lowering scientific or regulatory standards? In this interview, PJ Brooks explains how the National Center for Advancing Translational Sciences is shifting rare disease development toward platform-based thinking, shared molecular pathways, and early regulatory alignment. From genome editing and gene therapy to open…
USA Jeff Allen is the President & CEO of Friends of Cancer Research, a research policy and advocacy organisation based in Washington, DC. His organisation works to accelerate the development of cancer therapies through evidence-based policy and collaborative research partnerships. Allen highlights the importance of diagnostics and biomarker testing to help…
France As metabolic liver disease rises rapidly up the global health agenda, Professor Cyrielle Caussy stands at the intersection of clinical care, translational research, and therapeutic innovation. A Professor of Nutrition at Lyon 1 University and endocrinologist-diabetologist at Hospices Civils de Lyon, Caussy is a leading voice in metabolic dysfunction-associated steatotic…
France Professor Bana Jabri, Director of the Institut Imagine, brings a transatlantic perspective to advancing genetic medicine. After 25 years in the US, she now leads efforts in France to harness genomic technologies, foster interdisciplinary collaboration, and modernise academic–industry partnerships. Her vision calls for strategic investment, institutional autonomy, and greater risk…
Switzerland Prof. Andrea Alimonti, Director of the Institute of Oncology Research in Bellinzona, a leading Swiss centre focused on translational cancer research, shares his international journey from Rome to New York , Boston, and now Ticino, where he leads a growing, high-impact research institute. Under his leadership, IOR is expanding with…
See our Cookie Privacy Policy Here
